Proteochemometric modeling in a Bayesian framework
暂无分享,去创建一个
Isidro Cortes-Ciriano | Gerard J. P. van Westen | Therese E. Malliavin | Andreas Bender | Daniel S. Murrell | Eelke B. Lenselink | A. Bender | I. Cortés-Ciriano | T. Malliavin | E. B. Lenselink | G. V. Westen | G. Westen
[1] Kurt Hornik,et al. kernlab - An S4 Package for Kernel Methods in R , 2004 .
[2] H. V. van Vlijmen,et al. Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. , 2012, Journal of medicinal chemistry.
[3] Douglas M. Hawkins,et al. Assessing Model Fit by Cross-Validation , 2003, J. Chem. Inf. Comput. Sci..
[4] G. V. van Westen,et al. GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] Igor Kononenko,et al. An overview of advances in reliability estimation of individual predictions in machine learning , 2009, Intell. Data Anal..
[6] Michele Magrane,et al. UniProt Knowledgebase: a hub of integrated protein data , 2011, Database J. Biol. Databases Curation.
[7] Gerard J. P. van Westen,et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .
[8] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[9] Carl E. Rasmussen,et al. Gaussian Processes for Machine Learning (GPML) Toolbox , 2010, J. Mach. Learn. Res..
[10] Paola Gramatica,et al. The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .
[11] Christian Kramer,et al. QSARs, data and error in the modern age of drug discovery. , 2012, Current topics in medicinal chemistry.
[12] Peter C. Fox,et al. Statistical variation in progressive scrambling , 2004, J. Comput. Aided Mol. Des..
[13] Pekka Tiikkainen,et al. Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..
[14] John P. Overington,et al. A ligand's-eye view of protein similarity , 2013, Nature Methods.
[15] Frederick P. Roth,et al. Chemical substructures that enrich for biological activity , 2008, Bioinform..
[16] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[17] John P. Overington,et al. Global Analysis of Small Molecule Binding to Related Protein Targets , 2012, PLoS Comput. Biol..
[18] Frank R. Burden,et al. Quantitative Structure-Activity Relationship Studies Using Gaussian Processes , 2001, J. Chem. Inf. Comput. Sci..
[19] Peteris Prusis,et al. Proteochemometric modeling of HIV protease susceptibility , 2008, BMC Bioinformatics.
[20] Fuzhen Zhang. The Schur complement and its applications , 2005 .
[21] Klaus-Robert Müller,et al. Accurate Solubility Prediction with Error Bars for Electrolytes: A Machine Learning Approach , 2007, J. Chem. Inf. Model..
[22] A. Zeileis. Econometric Computing with HC and HAC Covariance Matrix Estimators , 2004 .
[23] Volker Tresp,et al. A Bayesian Committee Machine , 2000, Neural Computation.
[24] S. Wold,et al. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. , 1998, Journal of medicinal chemistry.
[25] Marvin Johnson,et al. Concepts and applications of molecular similarity , 1990 .
[26] Matthew D. Segall,et al. Gaussian Processes for Classification: QSAR Modeling of ADMET and Target Activity , 2010, J. Chem. Inf. Model..
[27] M. Murcko,et al. Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.
[28] Peng Zhou,et al. Gaussian process: an alternative approach for QSAM modeling of peptides , 2008, Amino Acids.
[29] Tropsha Alexander,et al. Predictive quantitative structure-activity relationships modeling: Development and validation of QSAR models , 2010 .
[30] Marc G. Genton,et al. Classes of Kernels for Machine Learning: A Statistics Perspective , 2002, J. Mach. Learn. Res..
[31] Davide Ballabio,et al. Evaluation of model predictive ability by external validation techniques , 2010 .
[32] Bin Wu,et al. Characterization of the binding profile of peptide to transporter associated with antigen processing (TAP) using Gaussian process regression , 2011, Comput. Biol. Medicine.
[33] Lehel Csató,et al. Sparse On-Line Gaussian Processes , 2002, Neural Computation.
[34] Scott P. Brown,et al. Healthy skepticism: assessing realistic model performance. , 2009, Drug discovery today.
[35] P. Prusis,et al. Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases. , 2013, Biochemical and biophysical research communications.
[36] Andreas Krause,et al. Navigating the protein fitness landscape with Gaussian processes , 2012, Proceedings of the National Academy of Sciences.
[37] Ola Spjuth,et al. Services for prediction of drug susceptibility for HIV proteases and reverse transcriptases at the HIV drug research centre , 2011, Bioinform..
[38] J. Skilling. Nested sampling for general Bayesian computation , 2006 .
[39] John P. Overington,et al. Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. , 2011, Current topics in medicinal chemistry.
[40] A. Tropsha,et al. Beware of q2! , 2002, Journal of molecular graphics & modelling.
[41] F. Tian,et al. Modeling and prediction of binding affinities between the human amphiphysin SH3 domain and its peptide ligands using genetic algorithm‐Gaussian processes , 2008, Biopolymers.
[42] G. V. van Westen,et al. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. , 2011, Trends in pharmacological sciences.
[43] Carl E. Rasmussen,et al. Gaussian processes for machine learning , 2005, Adaptive computation and machine learning.
[44] Michael Bieler,et al. The Role of Chemogenomics in the Pharmaceutical Industry , 2012 .
[45] D. Gloriam,et al. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. , 2009, Journal of medicinal chemistry.
[46] Oakland J. Peters,et al. Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.
[47] Gerard J. P. van Westen,et al. Significantly Improved HIV Inhibitor Efficacy Prediction Employing Proteochemometric Models Generated From Antivirogram Data , 2013, PLoS Comput. Biol..
[48] Geoffrey E. Hinton,et al. Bayesian Learning for Neural Networks , 1995 .
[49] Gilles Marcou,et al. Computational chemogenomics: Is it more than inductive transfer? , 2014, Journal of Computer-Aided Molecular Design.
[50] A. Vulpetti,et al. The experimental uncertainty of heterogeneous public K(i) data. , 2012, Journal of medicinal chemistry.
[51] Joshua B. Tenenbaum,et al. Structure Discovery in Nonparametric Regression through Compositional Kernel Search , 2013, ICML.
[52] Prabhat,et al. Parallelizing Gaussian Process Calculations in R , 2013, ArXiv.
[53] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[54] Zhiwei Cao,et al. Study on human GPCR-inhibitor interactions by proteochemometric modeling. , 2013, Gene.
[55] P. Prusis,et al. Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases. , 2008, Bioorganic & medicinal chemistry.
[56] Scott D. Kahn,et al. Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.
[57] David J. C. MacKay,et al. Information Theory, Inference, and Learning Algorithms , 2004, IEEE Transactions on Information Theory.
[58] A. Bender,et al. Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. , 2006, IDrugs : the investigational drugs journal.
[59] Johan Gottfries,et al. The drug designer´s guide to selectivity , 2006 .
[60] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[61] Zhiwei Cao,et al. Proteochemometric Modeling of the Bioactivity Spectra of HIV-1 Protease Inhibitors by Introducing Protein-Ligand Interaction Fingerprint , 2012, PloS one.
[62] Wendy A. Warr. Data sharing matters , 2014, Journal of Computer-Aided Molecular Design.
[63] Zheng Qifu,et al. Support Vector Machine Based on Universal Kernel Function and Its Application in Quantitative Structure - Toxicity Relationship Model , 2009, 2009 International Forum on Information Technology and Applications.
[64] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[65] Gunnar Rätsch,et al. Support Vector Machines and Kernels for Computational Biology , 2008, PLoS Comput. Biol..
[66] Max Kuhn,et al. Building Predictive Models in R Using the caret Package , 2008 .
[67] H. Mewes,et al. Can we estimate the accuracy of ADME-Tox predictions? , 2006, Drug discovery today.
[68] Gabriel Kronberger,et al. Evolution of Covariance Functions for Gaussian Process Regression Using Genetic Programming , 2013, EUROCAST.
[69] G. Schneider,et al. Combining on-chip synthesis of a focused combinatorial library with computational target prediction reveals imidazopyridine GPCR ligands. , 2014, Angewandte Chemie.
[70] Andreas Bender,et al. In Silico Target Predictions: Defining a Benchmarking Data Set and Comparison of Performance of the Multiclass Naïve Bayes and Parzen-Rosenblatt Window , 2013, J. Chem. Inf. Model..
[71] H. Kubinyi,et al. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. , 1998, Journal of medicinal chemistry.
[72] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[73] Michael T. M. Emmerich,et al. Chemogenomics: Looking at biology through the lens of chemistry , 2009, Stat. Anal. Data Min..
[74] H. V. van Vlijmen,et al. Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development , 2011, PloS one.
[75] Jun Gao,et al. Screening of selective histone deacetylase inhibitors by proteochemometric modeling , 2012, BMC Bioinformatics.
[76] A. Vulpetti,et al. Comparability of Mixed IC50 Data – A Statistical Analysis , 2013, PloS one.
[77] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[78] Andreas Bender,et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.
[79] Simo Puntanen,et al. Schur complements in statistics and probability , 2005 .
[80] Tomasz Arodz,et al. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. , 2006, Combinatorial chemistry & high throughput screening.
[81] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[82] Roberto Todeschini,et al. Comparison of Different Approaches to Define the Applicability Domain of QSAR Models , 2012, Molecules.
[83] A. Tropsha,et al. Predictive quantitative structure-activity relationship modeling , 2007 .
[84] Gábor Csányi,et al. Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties , 2007, J. Chem. Inf. Model..